Journal
FRONTIERS IN CHEMISTRY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2021.679120
Keywords
protac; protein kinase; inhibitors; degradation; anti-cancer
Categories
Funding
- National Natural Science Foundation of China [81960670]
- Science and Technology Plan Project of Science and Technology Department of Yunnan Province [202001AS070012, 2018FB145, 2019FB125]
Ask authors/readers for more resources
Kinase dysregulation is closely related to cell proliferation, migration, and survival. Consequently, kinases have been identified as important therapeutic targets for anti-cancer drug development. Traditional kinase inhibitors face challenges, but emerging technologies like PROTACs show promise in overcoming these limitations and improving targeted anti-cancer drug efficacy.
Kinase dysregulation is greatly associated with cell proliferation, migration and survival, indicating the importance of kinases as therapeutic targets for anticancer drug development. However, traditional kinase inhibitors binding to catalytic or allosteric sites are associated with significant challenges. The emergence of resistance and targeting difficult-to-degrade and multi-domain proteins are significant limiting factors affecting the efficacy of targeted anticancer drugs. The next-generation treatment approaches seem to have overcome these concerns, and the use of proteolysis targeting chimera (PROTAC) technology is one such method. PROTACs bind to proteins of interest and recruit E3 ligase for degrading the whole target protein via the ubiquitin-proteasome pathway. This review provides a detailed summary of the most recent signs of progress in PROTACs targeting different kinases, primarily focusing on new chemical entities in medicinal chemistry.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available